Abstract:Background Immune checkpoint inhibitors have become a standard therapeutic approach for cancer patients. Despite their impressive effects in treating solid tumors in certain clinical applications, the overall response rate (ORR) remains limited, hindering its wider use. This is at least partially attributed to inefficient biodistribution of therapeutic agents and insufficient infiltration of T cells within tumor microenvironment (TME). Therefore, methods to enhance the therapeutic effects of ICB are in high demand. Methods In this work, we produced both murine and humanized programmed cell death protein 1 (PD-1) antibody iRGD conjugates (αPD-1-(iRGD)2) through glycoengineering and bio-orthogonal reaction. The antitumor efficacy of αPD-1-(iRGD)2 was examined in murine tumor models. Biosafety and TME modulation were evaluated with histology, flow cytometry and RNA sequencing. Results iRGD modification largely refined the penetration of both PD-1 mAb and T cells. Besides, αPD-1-(iRGD)2 engages T cells and tumor cells thus promoting tumor elimination, which is not achievable by single agent αPD-1 or combination therapy. αPD-1-(iRGD)2 selectively engages and activates PD-1+ T cells which contains more tumor specific clusters. Systemic administration of αPD-1-(iRGD)2 elicited TME remodulation and impressive tumor growth control in various mouse tumor models with different immune infiltration characteristics, indicating αPD-1-(iRGD)2 might have broad-spectrum antitumor potential. During the regimen, no weight loss or main organ damage was observed. Furthermore, αPD-1-(iRGD)2 expands a unique population of T cells expressing stem and memory associated genes, which have been previously linked to tumor regression induced by αPD-1-IL2 conjugate (Nature 610, 161–172), so called 'better effector'. Conclusions In this work, we found that αPD-1-(iRGD)2 could enhance therapeutic potential for cancer treatment by simultaneously engaging T cells and tumor cells, promoting T cell infiltration and expanding a unique population of 'better effector' T cells. αPD-1-(iRGD)2 has the potential to be a novel and promising therapeutic approach for cancer immunotherapy. Ethics Approval All animal experiments were approved by the Institutional Animal Care and Use Committee of Drum Tower Hospital (approval number: 2020AE01064).

Combination immunotherapy of PEG-modified preladenant thermosensitive liposomes and PD-1 inhibitor effectively enhances the anti-tumor immune response and therapeutic effects

Local sustained release of PD-1 monoclonal antibody and lenvatinib by thermo-sensitive hydrogel for improving tumor immunotherapy

Thermal-sensitive lipid nanoparticles potentiate anti-PD therapy through enhancing drug penetration and T lymphocytes infiltration in metastatic tumor

Platelet Membrane Camouflaged AIEgen‐mediated Photodynamic Therapy Improves the Effectiveness of Anti‐pd‐l1 Immunotherapy in Large‐burden Tumors

PD-L1 antibody conjugated dihydrotanshinone I-loaded polymeric nanoparticle for targeted cancer immunotherapy combining PD-L1 blockade with immunogenic cell death

Mild photothermal therapy potentiates anti-PD-L1 treatment for immunologically cold tumors via an all-in-one and all-in-control strategy

In vivo activated T cell targeting with PD-1/PD-L1 blockade for sequential treatment mediated cancer immunotherapy

Anti-PD-L1 F(ab) Conjugated PEG-PLGA Nanoparticle Enhances Immune Checkpoint Therapy

Microfluidic PLGA microcapsules with PD-L1 aptamers and docetaxel encapsulation for enhancing tumor immunity

Mesoporous polydopamine Targeting CDK4/6 Inhibitor toward Brilliant Synergistic Immunotherapy of Breast Cancer

1197 Site-specific Anti-Pd-1-irgd Peptide Conjugate Boosts Antitumor Efficacy Via Enhancement of T Cell Penetration and Engagement

Precision Delivery of Dual Immune Inhibitors Loaded Nanomodulator to Reverse Immune Suppression for Combinational Photothermal-Immunotherapy

DPP Inhibition Enhances the Efficacy of PD-1 Blockade by Remodeling the Tumor Microenvironment in Lewis Lung Carcinoma Model

Photothermal Therapy Mediated by Phase-Transformation Nanoparticles Facilitates Delivery of Anti-Pd1 Antibody and Synergizes with Antitumor Immunotherapy for Melanoma

Pheophorbide A–Mediated Photodynamic Therapy Potentiates Checkpoint Blockade Therapy of Tumor with Low PD–L1 Expression

A cascade targeting strategy based on modified bacterial vesicles for enhancing cancer immunotherapy

Synergistic and low adverse effect cancer immunotherapy by immunogenic chemotherapy and locally expressed PD-L1 trap

Biomimetic Nanomodulators With Synergism of Photothermal Therapy and Vessel Normalization for Boosting Potent Anticancer Immunity

Harnessing PD-1 cell membrane-coated paclitaxel dimer nanoparticles for potentiated chemoimmunotherapy

A Bispecific Nanomodulator to Potentiate Photothermal Cancer Immunotherapy

Low-temperature Photothermal Irradiation Triggers Alkyl Radicals Burst for Potentiating Cancer Immunotherapy